Ii-Key/HER2/neu cancer vaccine: Interim Phase II data

Interim data from a single-blind, international Phase II trial in node-positive or high-risk, node-negative breast cancer patients with any degree of HER2 expression showed that AE37 plus GM-CSF reduc...